Spironolactone is associated with reduced risk of new-onset atrial fibrillation in patients receiving renal replacement therapy

Chung, Yi-WeiYi-WeiChungYang, Yao-HsuYao-HsuYangCHO-KAI WUCHIH-CHIEH YUJYH-MING JIMMY JUANGYI-CHIH WANGCHIA-TI TSAILIAN-YU LINLING-PING LAIHWANG, JUEY-JENJUEY-JENHWANGFU-TIEN CHIANGPAU-CHUNG CHENJIUNN-LEE LIN2022-09-202022-09-202016-01-010167-5273https://scholars.lib.ntu.edu.tw/handle/123456789/621204Whether the spironolactone treatment remains effective for the prevention of atrial fibrillation (AF) in dialysis patients is unclear.enAtrial fibrillation; ESRD; Hemodialysis; Spironolactone[SDGs]SDG3Spironolactone is associated with reduced risk of new-onset atrial fibrillation in patients receiving renal replacement therapyjournal article10.1016/j.ijcard.2015.05.167263238662-s2.0-84959859505WOS:000366161500246